AzTrials
AzTrials

Primary LymphedemaNCT01748604

Physical Therapies in the Decongestive Treatment of Lymphedema

A study testing Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC) and multilayer, multicomponent bandages (MB) in people with Primary Lymphedema and Secondary Lymphedema, run by Isabel Forner-Cordero, MD, PhD. at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this multicenter randomised controlled study is to determine whether manual lymphatic drainage (MLD) brings any benefit when added to intermittent pneumatic compression (IPC) plus multilayer, multicomponent bandages (MB) in the decongestive lymphatic therapy (DLT) in patients with lymphedema Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Primary Lymphedema, Secondary Lymphedema
What is being tested?
Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC) and multilayer, multicomponent bandages (MB)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
194 participants
Where
1 siteSpain
Study dates
Feb 2004to Jun 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • primary or secondary lymphedema,
  • lymphedema stages II or III
  • affecting unilateral upper or lower limb
  • Excess volume (EV) > 10%

Who cannot join

  • malignancy or active neoplasm disease or lack of information about it.
  • active lymphangitis
  • known contraindications for Decongestive Lymphatic Therapy (DLT): renal insufficiency, uncontrolled hypertension, cardiac disease and venous thrombosis.
  • a course of DLT during last year.
  • anything that could alter the patient's capability to consent truly to participate in this study

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • University Hospital La Fe

    Valencia, Valencia, 46026

Other trials in Spain

About this study

Official title: Physical Therapies in the Decongestive Treatment of Lymphedema: A Multicenter, Randomized, Controlled Study.

The purpose of this multicenter randomised controlled study is to determine whether manual lymphatic drainage (MLD) brings any benefit when added to intermittent pneumatic compression (IPC) plus multilayer, multicomponent bandages (MB) in the decongestive lymphatic therapy (DLT) in patients with lymphedema

Read the detailed description

Study Design: the study was a multicenter, randomized controlled study conducted at three university hospitals in Spain. Potential subjects were identified at Rehabilitation Department where physicians were responsible for screening subjects for eligibility and enrolling into the study.

Patients that fulfilled the inclusion criteria and signed up the informed consent were stratified within 2 stratums, upper and lower limb lymphedema, and then were randomized to one of the three treatment groups.

The type of randomization was a total randomization with ratio 1:1:1 and the method used to generate the random allocation sequence was a computer-generated random numbers table. Adequate randomization includes calling a central office once eligibility has been determined.

The physicians that assessed the outcome and the statistic who analyzed de data were blinded to the subjects' treatment assignment.

The study was approved by the Research Ethics Committee of the University Hospital La Fe. It was conducted according to the ethical principles laid down in the declaration of Helsinki (52nd World Medical Association General Assembly, Edinburgh, Scotland, October 2000) and the rules of best clinical practice.

Treatment Regimens: Patients were randomized to one of the following treatment groups:

  • Group A or control group: Manual Lymphatic Drainage (MLD) with Földi's technique by an expert therapist during 45 minutes; intermittent pneumatic compression (IPC) with multicompartmental pump between 50 to 80 mmHg during 30 minutes, followed by multilayer, multicomponent bandages (MB) until next day.
  • Group B: Pneumatic massage with Lymphapress-Plus(TM) device that was lent during the duration of the study during 20 minutes, and was supposed to open the proximal lymphatics at the root of the limb; IPC (50 to 80 mmHg during 30 minutes), followed by MB until next day.
  • Group C: IPC (50 to 80 mmHg during 30 minutes) followed by MB until next day.

All patients were planned to receive 20 sessions of treatment (5 per week in consecutive days during 4 consecutive weeks) and were trained in skin care and daily exercises.

After DLT, garments were prescribed and their adaptation was checked to warrant the maintenance of the results. The garments were flat knitted, custom made, generally class 2 (18-21 mmHg) for upper limb, and class 3 (36-46 mmHg) for lower limb.

Sample Size and Statistical analyses: This trial compares the efficacy of two treatment modalities without MLD (experimental group B and C) with a standard trimodal therapy (control group A). The expected effect size in percentage reduction in excess volume (PREV), primary end point, for the control group (MLD+IPC+MB) was defined from the review of literature and was 50 to 70% (mean 60%) with a standard deviation of 20 to 30 (mean 25). Our hypothesis was that there are no differences between experimental and standard treatment.

The required sample size for the study was 177 patients or 59 subjects per group to detect differences greater than or equal 15% in the percentage reduction in excess volume (PREV) between control and experimental groups, if exists; considering differences less than 15% as not clinically significant. It was based on an alpha error of 5% and a power of 90%. We estimated a drop-out rate of 10%. Therefore, 17 patients were added, resulting in a sample size of 194 subjects.

To compare baseline characteristics between three groups we use two-way ANOVA test for continuous variable and Pearson's chi2 for categorical data, to detect potential confounding factors. Outcome data were analyzed utilizing a two-way ANOVA test to assess differences between treatment groups with a 5% level of significance (p≤0.05) and two-tailed tests.

An exploratory subgroup analysis was made to identify factors associated with response (PREV). Factors for initial screening were identified by univariate linear regression model with a p value <0.1. In order to determine the independent predictive factors, a multivariate linear regression analysis was applied.

Being tested
Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC), multilayer, multicomponent bandages (MB), Lymphapress-Plus(TM) device (LPD)
Keywords
Lymphedema, Physical Therapies, Randomized controlled study, Decongestive lymphatic therapy, Manual lymph drainage, Intermittent pneumatic compression, Multilayer bandages
Medical subject headings
Lymphedema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Manual Lymphatic Drainage (MLD)Other

    MLD with Földi's technique by an expert therapist during 45 minutes

  • Generic intermittent pneumatic compression Device (IPC)Device

    Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.

  • multilayer, multicomponent bandages (MB)Other

    multilayer, multicomponent bandages (MB) until next day.

  • Lymphapress-Plus(TM) device (LPD)Device

    Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.

Study groups in NCT01748604
Study groupRoleWhat they receive
Standard trimodality therapy with MLDActive comparatorManual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
Receives: Other: Manual Lymphatic Drainage (MLD); Device: Generic intermittent pneumatic compression Device (IPC); Other: multilayer, multicomponent bandages (MB)
Trimodality therapy with LPDExperimentalPneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
Receives: Device: Generic intermittent pneumatic compression Device (IPC); Other: multilayer, multicomponent bandages (MB); Device: Lymphapress-Plus(TM) device (LPD)
Bimodality therapy without MLDExperimentalintermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
Receives: Device: Generic intermittent pneumatic compression Device (IPC); Other: multilayer, multicomponent bandages (MB)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage reduction in Excess Volume (PREV)

    It is obtained with the following formula: [(Initial EV - Final EV)/ Initial EV] x 100; where Excess Volume (EV) is the difference between Lymphedematous (VL) and Healthy limb volume (VH).

    Volumes were calculated with tape perimeter measurements (C) taken from the dorsum of the hand (C1) and repeated for every 4 cm proximally until the axilla (Cn), using Kuhnke formula, as the disk model is considered the method of choice in clinical practice.

    We assessed the change from baseline in PREV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.

    Measured: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT

Secondary outcomes (1)
  1. the Percentage of Volume reduction (PRV)

    it was calculated with the following formula: [(Initial VL - Final VL)/ Initial VL] x 100.

    We assessed the change from baseline in PRV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.

    Measured: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2012 (estimated)
  2. Study startFeb 2004
  3. Primary completionJan 2010
  4. Study completionJun 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
194 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01748604
Sponsor's protocol ID
HULaFe-LYMPHEDEMA-04
Status last verified
Dec 2012
First submitted
6 Dec 2012
Last updated
18 Dec 2012
Results posted
No
Data monitoring committee
Yes

Publications

  • Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology. 1998 Jun;31(2):56-64.

    PubMed 9664269
  • McNeely ML, Magee DJ, Lees AW, Bagnall KM, Haykowsky M, Hanson J. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 2004 Jul;86(2):95-106. doi: 10.1023/B:BREA.0000032978.67677.9f.

    PubMed 15319562
  • Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141. doi: 10.1002/14651858.CD003141.pub2.

    PubMed 15495042

Questions about this trial

What is this clinical trial studying?

A study testing Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC) and multilayer, multicomponent bandages (MB) in people with Primary Lymphedema and Secondary Lymphedema, run by Isabel Forner-Cordero, MD, PhD. at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage reduction in Excess Volume (PREV) (time frame: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01748604, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in